Allogeneic hematopoietic progenitor cell transplantation for the treatment of chronic myelogenous leukemia in the era of tyrosine kinase inhibitors: lessons learned to date.
Allogeneic hematopoietic stem cell transplantation with an human leukocyte antigen-matched related or unrelated donor has been the curative treatment of choice for young patients with chronic phase chronic myelogenous leukemia. The introduction of imatinib, a selective inhibitor of the Bcr-Abl protein kinase, as well as a new generation of other tyrosine kinase inhibitors that are effective in obtaining major and complete cytogenetic responses with minimal toxicity, has resulted in significant changes in the standard approach for newly diagnosed patients. In this article, we will address the role of allogeneic transplantation in the context of imatinib and other tyrosine kinase inhibitors.
Giralt
Sergio
S
Department of Stem Cell Transplantation and Cellular Therapies University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. e-mail: sgiralt@notes.mdacc.tmc.edu
D000293:Adolescent; D000328:Adult; D001549:Benzamides; D002648:Child; D002675:Child, Preschool; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000201:enzymology / Q000628:therapy*; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D014184:Transplantation, Homologous
D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl